{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:59:21Z","timestamp":1786996761836,"version":"build-2736575974"},"reference-count":43,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,19]],"date-time":"2020-12-19T00:00:00Z","timestamp":1608336000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006315","name":"ReumaNederland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006315","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.semarthrit.2020.11.006","type":"journal-article","created":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T04:13:57Z","timestamp":1608264837000},"page":"43-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["From incomplete to complete systemic lupus erythematosus; A review of the predictive serological immune markers"],"prefix":"10.1016","volume":"51","author":[{"given":"Wietske M.","family":"Lambers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Westra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrika","family":"Bootsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"de Leeuw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2020.11.006_bib0001","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/nrrheum.2016.186","article-title":"New insights into the immunopathogenesis of systemic lupus erythematosus","volume":"12","author":"Tsokos","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.11.006_bib0002","article-title":"How do patients with newly diagnosed SLE present? A multicenter cohort analysis to inform the development of new classification criteria for SLE","author":"Mosca","year":"2015","journal-title":"Arthritis Rheumatol Conf Am Coll Rheumatol Rheumatol Heal Prof Annu Sci Meet ACR\/ARHP"},{"key":"10.1016\/j.semarthrit.2020.11.006_bib0003","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/0961203307078579","article-title":"Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus","author":"James","year":"2007","journal-title":"Lupus"},{"key":"10.1016\/j.semarthrit.2020.11.006_bib0004","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kez292","article-title":"Damage accrual and mortality over long-term follow-up in 300 patients with systemic lupus erythematosus in a multi-ethnic British cohort","author":"Segura","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2020.11.006_bib0005","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/acr.22484","article-title":"We need better classification and terminology for \u201cpeople at high risk of or in the process of developing lupus","volume":"67","author":"Costenbader","year":"2015","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2020.11.006_bib0006","doi-asserted-by":"crossref","DOI":"10.1002\/acr.22583","article-title":"Distinctions between diagnostic and classification criteria?","author":"Aggarwal","year":"2015","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2020.11.006_bib0007","first-page":"1271","article-title":"The 1982 revised criteria for the classification of systemic lupus erythematosus","volume":"25","author":"Cohen","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.11.006_bib0008","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/art.34473","article-title":"Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.11.006_bib0009","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2018-214819","article-title":"European league against rheumatism\/American college of rheumatology classification criteria for systemic lupus erythematosus","author":"Aringer","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.11.006_bib0010","doi-asserted-by":"crossref","DOI":"10.1191\/096120300678828073","article-title":"Clinical outcome and predictors of disease evolution in patients with incomplete lupus erythematosus","author":"Vil\u00e1","year":"2000","journal-title":"Lupus"},{"key":"10.1016\/j.semarthrit.2020.11.006_bib0011","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1191\/0961203304lu477oa","article-title":"Outcome of incomplete systemic lupus erythematosus after 10 years","volume":"13","author":"Hallengren","year":"2004","journal-title":"Lupus"},{"key":"10.1016\/j.semarthrit.2020.11.006_bib0012","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1002\/art.1780381014","article-title":"Identification of patient subsets among those presumptively diagnosed with, referred, and\/or followed up for systemic lupus erythematosus at a large tertiary care center","volume":"38","author":"Calvo-Al\u00e9n","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.11.006_bib0013","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/rheumatology\/40.1.89","article-title":"Incomplete lupus erythematosus: results of a multicentre study under the supervision of the EULAR standing committee on international clinical studies including therapeutic trials (ESCISIT)","volume":"40","author":"Swaak","year":"2001","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2020.11.006_bib0014","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.12466","article-title":"Development of SLE among \u201cpotential SLE\u201d patients seen in consultation: long-term follow-up","author":"Al Daabil","year":"2014","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.semarthrit.2020.11.006_bib0015","article-title":"Incomplete systemic lupus erythematosus \u2013 what remains after application of ACR and SLICC criteria?","author":"Lambers","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2020.11.006_bib0016","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1056\/NEJMoa021933","article-title":"Development of autoantibodies before the clinical onset of systemic lupus erythematosus","volume":"349","author":"Arbuckle","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2020.11.006_bib0017","doi-asserted-by":"crossref","first-page":"R30","DOI":"10.1186\/ar3258","article-title":"Autoantibodies predate the onset of systemic lupus erythematosus in northern Sweden","volume":"13","author":"Eriksson","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2020.11.006_bib0018","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1002\/art.21379","article-title":"Inhibition of lupus disease by anti-double-stranded DNA antibodies of the IgM isotype in the (NZB\u00a0\u00d7\u00a0NZW)F1 mouse","volume":"52","author":"Werwitzke","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.11.006_bib0019","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s12016-007-8046-x","article-title":"IgM antibodies against dsDNA in SLE","volume":"34","author":"Witte","year":"2008","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.semarthrit.2020.11.006_bib0020","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1365-2249.2006.03251.x","article-title":"Protein array autoantibody profiles for insights into systemic lupus erythematosus and incomplete lupus syndromes","volume":"147","author":"Li","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.semarthrit.2020.11.006_bib0021","doi-asserted-by":"crossref","first-page":"R174","DOI":"10.1186\/ar3927","article-title":"Autoantibody profiling to follow evolution of lupus syndromes","volume":"14","author":"Olsen","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2020.11.006_bib0022","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1038\/jid.2012.207","article-title":"IgG and IgM autoantibody differences in discoid and systemic lupus patients","volume":"132","author":"Chong","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.semarthrit.2020.11.006_bib0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s10020-018-0019-4","article-title":"Serologic features of cohorts with variable genetic risk for systemic lupus erythematosus","volume":"24","author":"Bhattacharya","year":"2018","journal-title":"Mol Med"},{"key":"10.1016\/j.semarthrit.2020.11.006_bib0024","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/art.40004","article-title":"Discerning risk of disease transition in relatives of systemic lupus erythematosus patients utilizing soluble mediators and clinical features","volume":"69","author":"Munroe","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.11.006_bib0025","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.4049\/jimmunol.1002795","article-title":"Type I Interferon in the Pathogenesis of lupus","volume":"192","author":"Crow","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.semarthrit.2020.11.006_bib0026","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1136\/ard.2004.033753","article-title":"Type I interferon correlates with serological and clinical manifestations of SLE","volume":"64","author":"Dall'Era","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.11.006_bib0027","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1002\/art.30187","article-title":"Network analysis of associations between serum interferon-\u03b1 activity, autoantibodies, and clinical features in systemic lupus erythematosus","volume":"63","author":"Weckerle","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.11.006_bib0028","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.berh.2017.10.003","article-title":"Role of interferons in SLE","volume":"31","author":"Bengtsson","year":"2017","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.11.006_bib0029","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1007\/s10067-018-4138-7","article-title":"Higher activation of the interferon-gamma signaling pathway in systemic lupus erythematosus patients with a high type I IFN score: relation to disease activity","volume":"37","author":"Liu","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.11.006_bib0030","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.4049\/jimmunol.181.3.2211","article-title":"Excessive production of IFN - in patients with systemic lupus erythematosus and its contribution to induction of B lymphocyte stimulator\/B cell-activating factor\/TNF ligand superfamily-13B","volume":"181","author":"Harigai","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.semarthrit.2020.11.006_bib0031","doi-asserted-by":"crossref","DOI":"10.1002\/art.38628","article-title":"Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type i and type ii interferon signatures","author":"Chiche","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.11.006_bib0032","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1365-2249.2009.04057.x","article-title":"Interferon signature gene expression is correlated with autoantibody profiles in patients with incomplete lupus syndromes","volume":"159","author":"Li","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.semarthrit.2020.11.006_bib0033","doi-asserted-by":"crossref","unstructured":"Lambers WM, Leeuw K De, Doornbos BD, Diercks GFH, Bootsma H, Westra J. Interferon score is increased in incomplete systemic lupus erythematosus and correlates with myxovirus-resistance protein A in blood and skin. Arthritis Research & Therapy (2019) 21:260. doi: 10.1186\/s13075-019-2034-42019;4:1\u201313.","DOI":"10.1186\/s13075-019-2034-4"},{"key":"10.1016\/j.semarthrit.2020.11.006_bib0034","first-page":"1","article-title":"MxA is a clinically applicable biomarker for type I interferon activation in systemic lupus erythematosus and systemic sclerosis","author":"Huijser","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2020.11.006_bib0035","first-page":"1","article-title":"Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status","author":"Md Yusof","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.11.006_bib0036","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1136\/annrheumdis-2015-208140","article-title":"Altered type II interferon precedes autoantibody accrual and elevated type i interferon activity prior to systemic lupus erythematosus classification","volume":"75","author":"Munroe","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.11.006_bib0037","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1177\/0961203314523869","article-title":"Cytokines in relation to autoantibodies before onset of symptoms for systemic lupus erythematosus","volume":"23","author":"Eriksson","year":"2014","journal-title":"Lupus"},{"key":"10.1016\/j.semarthrit.2020.11.006_bib0038","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jaut.2016.06.001","article-title":"Dysregulation of innate and adaptive serum mediators precedes systemic lupus erythematosus classification and improves prognostic accuracy of autoantibodies","volume":"74","author":"Lu","year":"2016","journal-title":"J Autoimmun"},{"key":"10.1016\/j.semarthrit.2020.11.006_bib0039","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/lupus-2014-000056","article-title":"Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements","volume":"1","author":"Putterman","year":"2014","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.semarthrit.2020.11.006_bib0040","doi-asserted-by":"crossref","DOI":"10.1002\/art.34669","article-title":"Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus","author":"Kalunian","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.11.006_bib0041","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1002\/art.20561","article-title":"Measurement of erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus","volume":"50","author":"Manzi","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.11.006_bib0042","series-title":"Complement activation occurs in patients with probable systemic lupus erythematosus and may predict progression to ACR classified SLE","author":"Ramsey-Goldman","year":"2019"},{"key":"10.1016\/j.semarthrit.2020.11.006_bib0043","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jim.2017.04.001","article-title":"Validation of a multi-analyte panel with cell-bound complement activation products for systemic lupus erythematosus","volume":"446","author":"Dervieux","year":"2017","journal-title":"J Immunol Methods"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017220302948?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017220302948?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:03:24Z","timestamp":1758733404000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017220302948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0049017220302948"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2020.11.006","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From incomplete to complete systemic lupus erythematosus; A review of the predictive serological immune markers","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2020.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}